1. Omega-3 fatty acids plus rosuvastatin improves endothelial function in South Asians with dyslipidemia.
- Author
-
Mindrescu C, Gupta RP, Hermance EV, DeVoe MC, Soma VR, Coppola JT, and Staniloae CS
- Subjects
- Adult, Aged, Asia ethnology, Cross-Over Studies, Drug Therapy, Combination, Dyslipidemias ethnology, Dyslipidemias physiopathology, Endothelium, Vascular physiopathology, Female, Humans, Lipids blood, Male, Middle Aged, New York epidemiology, Rosuvastatin Calcium, Time Factors, Treatment Outcome, Asian People, Dyslipidemias drug therapy, Endothelium, Vascular drug effects, Fatty Acids, Omega-3 therapeutic use, Fluorobenzenes therapeutic use, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Pyrimidines therapeutic use, Sulfonamides therapeutic use, Vasodilation drug effects, Vasodilator Agents therapeutic use
- Abstract
Background: The present study was undertaken to investigate the effect of statins plus omega-3 polyunsaturated fatty acids (PUFAs) on endothelial function and lipid profile in South Asians with dyslipidemia and endothelial dysfunction, a population at high risk for premature coronary artery disease., Methods: Thirty subjects were randomized to rosuvastatin 10 mg and omega-3-PUFAs 4 g or rosuvastatin 10 mg. After 4 weeks, omega-3-PUFAs were removed from the first group and added to subjects in the second group. All subjects underwent baseline, 4-, and 8-week assessment of endothelial function and lipid profile., Results: Compared to baseline, omega-3-PUFAs plus rosuvastatin improved endothelial-dependent vasodilation (EDV: -1.42% to 11.36%, p = 0.001), and endothelial-independent vasodilation (EIV: 3.4% to 17.37%, p = 0.002). These effects were lost when omega-3-PUFAs were removed (EDV: 11.36% to 0.59%, p = 0.003). In the second group, rosuvastatin alone failed to improve both EDV and EIV compared to baseline. However, adding omega-3-PUFAs to rosuvastatin, significantly improved EDV (-0.66% to 14.73%, p = 0.001) and EIV (11.02% to 24.5%, p = 0.001). Addition of omega-3-PUFAs further improved the lipid profile (triglycerides 139 to 91 mg/dl, p = 0.006, low-density lipoprotein cholesterol 116 to 88 mg/dl, p = 0.014)., Conclusions: Combined therapy with omega-3-PUFAs and rosuvastatin improves endothelial function in South Asian subjects with dyslipidemia and endothelial dysfunction.
- Published
- 2008
- Full Text
- View/download PDF